Phase 3 Myasthenia Gravis Study of the FcRn Antagonist Efgartigimod

Time: 4:15 pm
day: Day One

Details:

• Brief overview of Myasthenia Gravis and diving into the novel mode of action of efgartigimod

• Evaluating Phase 3 ADAPT trial design and redosing strategy based on patient symptoms, an individualized treatment approach

• Assessing the safety and efficacy of efgartigimod in patients including secondary endpoints and prespecified analyses

Speakers: